ArticleClinical and translational science2025

Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.

Akihiro Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.